Veterinary Medicines

Hipraviar NDV-CLON Lyofilisaat voor suspensie voor oculonasaal gebruik/voor gebruik in drinkwater

Authorised
  • Newcastle disease virus, strain CLON CL/79, Live
Download as PDF

Product identification

Medicine name:
Hipraviar NDV-CLON Lyofilisaat voor suspensie voor oculonasaal gebruik/voor gebruik in drinkwater
Hipraviar NDV-CLON Lyophilisat pour suspension oculonasale/administration dans l'eau de boisson
Hipraviar NDV-CLON Lyophilisat zur Herstellung einer Suspension zur oculonasalen Anwendung/zum Eingeben über das Trinkwasser
Active substance:
  • Newcastle disease virus, strain CLON CL/79, Live
Target species:
  • Chicken (broiler)
Route of administration:
  • Nebulisation use
  • In drinking water use
  • Oculonasal use

Product details

Active substance and strength:
  • Newcastle disease virus, strain CLON CL/79, Live
    6.50
    log 10 50% embryo infective dose
    /
    0.03
    millilitre(s)
Pharmaceutical form:
  • Lyophilisate for oculonasal suspension/use in drinking water
Withdrawal period by route of administration:
  • Nebulisation use
    • Chicken (broiler)
      • Meat and offal
        no withdrawal period
  • In drinking water use
    • Chicken (broiler)
      • Meat and offal
        no withdrawal period
  • Oculonasal use
    • Chicken (broiler)
      • Meat and offal
        no withdrawal period
Anatomical therapeutic chemical veterinary (ATCvet) codes:
  • QI01AD06
Legal status of supply:
  • Veterinary medicinal product subject to veterinary prescription
Authorisation status:
  • Valid
Authorised in:
  • Belgium
Package description:
  • Hipraviar NDV-CLON 10 Vials with 5000 doses with Powder for solution
  • Hipraviar NDV-CLON 10 Vials with 1000 doses with Powder for solution and 10 Vials with 75 ml with solvent
  • Hipraviar NDV-CLON 10 Vials with 1000 doses with Powder for solution and 10 Vials with 30 ml with solvent
  • Hipraviar NDV-CLON 5 Vials with 1000 doses with Powder for solution and 5 Vials with 30 ml with solvent

Additional information

Entitlement type:
  • Marketing Authorisation
Legal basis of product authorisation:
  • Full application (Article 12(3) of Directive No 2001/82/EC)
Marketing authorisation holder:
  • Laboratorios Hipra S.A.
Marketing authorisation date:
Manufacturing sites for batch release:
  • Laboratorios Hipra S.A.
Responsible authority:
  • Federal Agency For Medicines And Health Products
Authorisation number:
  • BE-V193593
Date of authorisation status change:

Documents

Summary of Product Characteristics

This document does not exist in this language (English). You can find it in another language below.
Dutch (PDF)
Published on: 22/03/2022
Download
French (PDF)
Published on: 22/03/2022
Download

Package Leaflet

This document does not exist in this language (English). You can find it in another language below.
Dutch (PDF)
Published on: 22/03/2022
Download
French (PDF)
Published on: 22/03/2022
Download
German (PDF)
Published on: 22/03/2022
Download
How useful was this page?:
No votes yet
"Please do not include any personal data, such as your name or contact details. If you do, you consent to the processing of that data in accordance with EMA’s Privacy Statement concerning requests for information or access to documents. If you would like a reply from EMA, please Send a question to EMA instead."